期刊
BIOMARKERS
卷 16, 期 1, 页码 74-82出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2010.533284
关键词
Gastric cancer; 5-fluorouracil; cisplatin; ERCC1; GSTP1
资金
- MEST/NRF [2009-0090896]
- Korea Science and Engineering Foundation through the Medical Research Center for Cancer Molecular Therapy at Dong-A University [R13-2002-044-05002-0]
The objective of this study was to determine whether the expressions of the excision cross-complementing (ERCC1), thymidylate synthase (TS) and glutathione S-transferase P1 (GSTP1) are predictive of clinical outcomes in advanced gastric cancer (AGC) patients receiving treatment with adjuvant 5-fluorouracil (5-FU) and cisplatin (FP) chemotherapy. One hundred forty nine patients were included in this study. ERCC1 and GSTP1 expression was correlated significantly with tumor size (p = 0.040, p = 0.018, respectively). Stage and positive lymph node ratio were associated independently with disease free survival (DFS) and overall survival (OS). Both ERCC1 and GSTP1 expression had a significant impact on OS (hazard ratio = 0.069, p = 0.021). TS expression was not related to DFS and OS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据